The glycocalyx and its significance in human medicine

Journal of Internal Medicine

Volumn 280, Issue 1, 2016, Pages 97-113

  Tarbell, J M ^a   Cancel, L M ^a  

^a City University of New York   (United States)

Author keywords

atherosclerosis; cancer metastasis; glycocalyx; matrix metalloproteinase; mechanotransduction

Indexed keywords

4 METHLESCULETIN; ALBUMIN; CRATAEGUS EXTRACT; GLYPICAN; HEPARAN SULFATE; HYALURONIC ACID; HYMECROMONE; MATRIX METALLOPROTEINASE; MICRORNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A6; PENTOSAN POLYSULFATE; RECOMBINANT HYALURONIDASE; SULODEXIDE; SYNDECAN; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; CANCER THERAPY; CELL GROWTH; CELL MOTILITY; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCOCALYX; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MECHANOTRANSDUCTION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SHEAR STRESS; TUMOR GROWTH;

EID: 84975123130     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12465     Document Type: Review

References (131)

1. Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol 2015; 80: 389–402.
2. Fu BM, Tarbell JM. Mechano-sensing and transduction by endothelial surface glycocalyx: composition, structure, and function. Wiley Interdiscip Rev Syst Biol Med 2013; 5: 381–90.
3. Tarbell JM, Shi ZD, Dunn J, Jo H. Fluid Mechanics, Arterial Disease, and Gene Expression. Annu Rev Fluid Mech 2014; 46: 591–614.
4. Tarbell JM, Simon SI, Curry FR. Mechanosensing at the vascular interface. Annu Rev Biomed Eng 2014; 16: 505–32.
5. Tarbell JM, Pahakis MY. Mechanotransduction and the glycocalyx. J Intern Med 2006; 259: 339–50.
6. Varki A, Kannagi R, Toole BP. Glycosylation Changes in Cancer. 2009.
7. Rambourg A, Neutra M, Leblond CP. Presence of a “cell coat” rich in carbohydrate at the surface of cells in the rat. Anat Rec 1966; 154: 41–71.
8. Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc 1966; 25: 1773–83.
9. Ebong EE, Macaluso FP, Spray DC, Tarbell JM. Imaging the endothelial glycocalyx in vitro by rapid freezing/freeze substitution transmission electron microscopy. Arterioscler Thromb Vasc Biol 2011; 31: 1908–15.
10. Frey A, Giannasca KT, Weltzin R et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184: 1045–59.
11. Kesimer M, Ehre C, Burns KA, Davis CW, Sheehan JK, Pickles RJ. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol 2013; 6: 379–92.
12. Ainslie KM, Garanich JS, Dull RO, Tarbell JM. Vascular smooth muscle cell glycocalyx influences shear stress-mediated contractile response. J Appl Physiol (1985) 2005; 98: 242–9.
13. Kang H, Liu M, Fan Y, Deng X. A potential gravity-sensing role of vascular smooth muscle cell glycocalyx in altered gravitational stimulation. Astrobiology 2013; 13: 626–36.
14. Qazi H, Palomino R, Shi ZD, Munn LL, Tarbell JM. Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion. Integr Biol (Camb) 2013; 5: 1334–43.
15. Yang C, Liu Y, He Y et al. The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy. Biomaterials 2013; 34: 6829–38.
16. Weinbaum S, Duan Y, Thi MM, You L. An integrative review of mechanotransduction in endothelial, epithelial (renal) and dendritic cells (Osteocytes). Cell Mol Bioeng 2011; 4: 510–37.
17. Reilly GC, Haut TR, Yellowley CE, Donahue HJ, Jacobs CR. Fluid flow induced PGE2 release by bone cells is reduced by glycocalyx degradation whereas calcium signals are not. Biorheology 2003; 40: 591–603.
18. Burra S, Nicolella DP, Francis WL et al. Dendritic processes of osteocytes are mechanotransducers that induce the opening of hemichannels. Proc Natl Acad Sci U S A 2010; 107: 13648–53.
19. Henderson-Toth CE, Jahnsen ED, Jamarani R, Al-Roubaie S, Jones EA. The glycocalyx is present as soon as blood flow is initiated and is required for normal vascular development. Dev Biol 2012; 369: 330–9.
20. Gasimli L, Linhardt RJ, Dordick JS. Proteoglycans in stem cells. Biotechnol Appl Biochem 2012; 59: 65–76.
21. Nikmanesh M, Shi ZD, Tarbell JM. Heparan sulfate proteoglycan mediates shear stress-induced endothelial gene expression in mouse embryonic stem cell-derived endothelial cells. Biotechnol Bioeng 2012; 109: 583–94.
22. Zeng Y, Ebong EE, Fu BM, Tarbell JM. The structural stability of the endothelial glycocalyx after enzymatic removal of glycosaminoglycans. PLoS One 2012; 7: e43168.
23. Adamson RH, Clough G. Plasma proteins modify the endothelial cell glycocalyx of frog mesenteric microvessels. J Physiol 1992; 445: 473–86.
24. Curry FRE, Adamson RH. Sphingosine-1-phosphate and the “albumin effect” on rat venular microvessels. Faseb J 2013; 27: 896.2.
25. Zeng Y, Adamson RH, Curry FR, Tarbell JM. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol 2014; 306: H363–72.
26. Rahbar E, Cardenas JC, Baimukanova G et al. Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients. J Transl Med 2015; 13: 117.
27. Giantsos-Adams KM, Koo AJ, Song S et al. Heparan Sulfate Regrowth Profiles Under Laminar Shear Flow Following Enzymatic Degradation. Cell Mol Bioeng 2013; 6: 160–74.
28. Koo A, Dewey CF Jr, Garcia-Cardena G. Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. Am J Physiol Cell Physiol 2013; 304: C137–46.
29. Lewis JC, Taylor RG, Jones ND, St Clair RW, Cornhill JF. Endothelial surface characteristics in pigeon coronary artery atherosclerosis. I. Cellular alterations during the initial stages of dietary cholesterol challenge. Lab Invest 1982; 46: 123–38.
30. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol 2006; 290: H915–20.
31. Cancel LM, Ebong EE, Tarbell JM. Endothelial Glycocalyx and Apoptosis in Atherosclerosis. FASEB J 2015; 29: 631.3.
32. van den Berg BM, Spaan JA, Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch 2009; 457: 1199–206.
33. Nagy N, Freudenberger T, Melchior-Becker A et al. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation 2010; 122: 2313–22.
34. Son DJ, Kumar S, Takabe W et al. The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 2013; 4: 3000.
35. Kim MH, Harris NR, Korzick DH, Tarbell JM. Control of the arteriolar myogenic response by transvascular fluid filtration. Microvasc Res 2004; 68: 30–7.
36. Shi ZD, Wang H, Tarbell JM. Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen. PLoS One 2011; 6: e15956.
37. Skalsky I, Szarszoi O, Filova E et al. A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study. Int J Pharm 2012; 427: 311–9.
38. Shi ZD, Tarbell JM. Fluid flow mechanotransduction in vascular smooth muscle cells and fibroblasts. Ann Biomed Eng 2011; 13138: 1608–19.
39. Ueno M, Sakamoto H, Liao YJ et al. Blood-brain barrier disruption in the hypothalamus of young adult spontaneously hypertensive rats. Histochem Cell Biol 2004; 122: 131–7.
40. Ueno M, Sakamoto H, Tomimoto H et al. Blood-brain barrier is impaired in the hippocampus of young adult spontaneously hypertensive rats. Acta Neuropathol 2004; 107: 532–8.
41. Martens RJ, Vink H, van Oostenbrugge RJ, Staals J. Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc Dis 2013; 35: 451–4.
42. Richter V, Savery MD, Gassmann M, Baum O, Damiano ER, Pries AR. Excessive erythrocytosis compromises the blood-endothelium interface in erythropoietin-overexpressing mice. J Physiol 2011; 589: 5181–92.
43. Sehba FA, Ding WH, Chereshnev I, Bederson JB. Effects of S-nitrosoglutathione on acute vasoconstriction and glutamate release after subarachnoid hemorrhage. Stroke 1999; 30: 1955–61.
44. Ostrowski SR, Gaini S, Pedersen C, Johansson PI. Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: an observational study. J Crit Care 2015; 30: 90–6.
45. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254: 194–200.
46. Sallisalmi M, Tenhunen J, Yang R, Oksala N, Pettila V. Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesthesiol Scand 2012; 56: 316–22.
47. Steppan J, Hofer S, Funke B et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix. J Surg Res 2011; 165: 136–41.
48. Donati A, Damiani E, Domizi R et al. Alteration of the sublingual microvascular glycocalyx in critically ill patients. Microvasc Res 2013; 90: 86–9.
49. Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 2009; 114: 3033–43.
50. Schmidt EP, Yang Y, Janssen WJ et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 2012; 18: 1217–23.
51. Marechal X, Favory R, Joulin O et al. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 2008; 29: 572–6.
52. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol 1978; 93: 526–618.
53. Ratliff BB, Rabadi MM, Vasko R, Yasuda K, Goligorsky MS. Messengers without borders: mediators of systemic inflammatory response in AKI. J Am Soc Nephrol 2013; 24: 529–36.
54. Zullo JA, Fan J, Azar TF, Yen W, Zeng M, Chen J et al. Exocytosis of endothelial lysosome-related organelles hair-triggers a patchy loss of glycocalyx at the onset of sepsis. Am J Pathol 2015 (in press).
55. Lopez-Quintero SV, Cancel LM, Pierides A, Antonetti D, Spray DC, Tarbell JM. High glucose attenuates shear-induced changes in endothelial hydraulic conductivity by degrading the glycocalyx. PLoS One 2013; 8: e78954.
56. Brower JB, Targovnik JH, Caplan MR, Massia SP. High glucose-mediated loss of cell surface heparan sulfate proteoglycan impairs the endothelial shear stress response. Cytoskeleton (Hoboken) 2010; 67: 135–41.
57. Danese C, Vestri AR, D'Alfonso V et al. Do hypertension and diabetes mellitus influence the site of atherosclerotic plaques? Clin Ter 2006; 157: 9–13.
58. Reyes-Soffer G, Holleran S, Di Tullio MR et al. Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism 2010; 59: 1365–71.
59. Vlahu CA, Lemkes BA, Struijk DG, Koopman MG, Krediet RT, Vink H. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 2012; 23: 1900–8.
60. Salmon AH, Ferguson JK, Burford JL et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012; 23: 1339–50.
61. Padberg JS, Wiesinger A, di Marco GS et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234: 335–43.
62. Ramnath R, Foster RR, Qiu Y et al. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha: a contributor to endothelial cell glycocalyx dysfunction. FASEB J 2014; 28: 4686–99.
63. Neves FM, Meneses GC, Sousa NE et al. Syndecan-1 in acute decompensated heart failure- association with renal function and mortality. Circ J 2015; 79: 1511–9.
64. Kumase F, Morizane Y, Mohri S, Takasu I, Ohtsuka A, Ohtsuki H. Glycocalyx degradation in retinal and choroidal capillary endothelium in rats with diabetes and hypertension. Acta Med Okayama 2010; 64: 277–83.
65. Kusche-Vihrog K, Oberleithner H. An emerging concept of vascular salt sensitivity. F1000 Biol Rep 2012; 4: 20.
66. Oberleithner H. Vascular endothelium: a vulnerable transit zone for merciless sodium. Nephrol Dial Transplant 2014; 29: 240–6.
67. Pot C, Chen AY, Ha JN, Schmid-Schonbein GW. Proteolytic cleavage of the red blood cell glycocalyx in a genetic form of hypertension. Cell Mol Bioeng 2011; 4: 678–92.
68. Collins SR, Blank RS, Deatherage LS, Dull RO. Special article: the endothelial glycocalyx: emerging concepts in pulmonary edema and acute lung injury. Anesth Analg 2013; 117: 664–74.
69. Yang Y, Schmidt EP. The endothelial glycocalyx: an important regulator of the pulmonary vascular barrier. Tissue Barriers 2013; 1: e23494.
70. Strunden MS, Bornscheuer A, Schuster A, Kiefmann R, Goetz AE, Heckel K. Glycocalyx degradation causes microvascular perfusion failure in the ex vivo perfused mouse lung: hydroxyethyl starch 130/0.4 pretreatment attenuates this response. Shock 2012; 38: 559–66.
71. Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 2014; 4: 195.
72. Belting M, Borsig L, Fuster MM et al. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci U S A 2002; 99: 371–6.
73. Esko JD, Rostand KS, Weinke JL. Tumor formation dependent on proteoglycan biosynthesis. Science 1988; 241: 1092–6.
74. Fuster MM, Wang L, Castagnola J et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol 2007; 177: 539–49.
75. Llaneza A, Vizoso F, Rodriguez JC et al. Hyaluronic acid as prognostic marker in resectable colorectal cancer. Br J Surg 2000; 87: 1690–6.
76. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 3–14.
77. Paszek MJ, Boettiger D, Weaver VM, Hammer DA. Integrin clustering is driven by mechanical resistance from the glycocalyx and the substrate. PLoS Comput Biol 2009; 5: e1000604.
78. Walker JL, Fournier AK, Assoian RK. Regulation of growth factor signaling and cell cycle progression by cell adhesion and adhesion-dependent changes in cellular tension. Cytokine Growth Factor Rev 2005; 16: 395–405.
79. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9–22.
80. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009; 106: 10290–5.
81. Paszek MJ, DuFort CC, Rossier O et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 2014; 511: 319–25.
82. Bernfield M, Gotte M, Park PW et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729–77.
83. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446: 1030–7.
84. Couchman JR, Chen L, Woods A. Syndecans and cell adhesion. Int Rev Cytol 2001; 207: 113–50.
85. Harfouche R, Hentschel DM, Piecewicz S et al. Glycome and transcriptome regulation of vasculogenesis. Circulation 2009; 120: 1883–92.
86. Lee D, Oh ES, Woods A, Couchman JR, Lee W. Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5-bisphosphate. J Biol Chem 1998; 273: 13022–9.
87. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1–16.
88. Gotte M, Kersting C, Radke I, Kiesel L, Wulfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007; 9: R8.
89. Zhang Y, Wang N, Raab RW et al. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity. J Biol Chem 2013; 288: 12090–101.
90. Choi S, Lee E, Kwon S et al. Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 2005; 280: 42573–9.
91. Ma P, Beck SL, Raab RW et al. Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J Cell Biol 2006; 174: 1097–106.
92. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005; 310: 205–17.
93. Krahling H, Mally S, Eble JA, Noel J, Schwab A, Stock C. The glycocalyx maintains a cell surface pH nanoenvironment crucial for integrin-mediated migration of human melanoma cells. Pflugers Arch 2009; 458: 1069–83.
94. Van Sluis GL, Nieuwdorp M, Kamphuisen PW, van der Vlag J, Van Noorden CJ, Spek CA. A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx. PLoS One 2010; 5: e11200.
95. Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK. Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma. Radiother Oncol 2014; 113: 132–8.
96. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol 2010; 105: 687–701.
97. Suarez JI, Martin RH, Calvillo E, Bershad EM, Venkatasubba Rao CP. Effect of human albumin on TCD vasospasm, DCI, and cerebral infarction in subarachnoid hemorrhage: the ALISAH study. Acta Neurochir Suppl 2015; 120: 287–90.
98. Kozar RA, Peng Z, Zhang R et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 2011; 112: 1289–95.
99. Taylor DO, Edwards LB, Boucek MM et al. Registry of the international society for heart and lung transplantation: twenty-fourth official adult heart transplant report–2007. J Heart Lung Transplant 2007; 26: 769–81.
100. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 2006; 290: E1–8.
101. Broekhuizen LN, Lemkes BA, Mooij HL et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 2646–55.
102. Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol 2014; 33: 243–54.
103. Frati Munari AC. Medical significance of endothelial glycocalyx. Part 2: its role in vascular diseases and in diabetic complications. Arch Cardiol Mex 2014; 84: 110–6.
104. Illien-Junger S, Grosjean F, Laudier DM, Vlassara H, Striker GE, Iatridis JC. Combined anti-inflammatory and anti-AGE drug treatments have a protective effect on intervertebral discs in mice with diabetes. PLoS One 2013; 8: e64302.
105. Harada N, Maeda M. Chemical structure of antithrombin-active Rhamnan sulfate from Monostrom nitidum. Biosci Biotechnol Biochem 1998; 62: 1647–52.
106. Lee JB, Hayashi K, Hayashi T, Sankawa U, Maeda M. Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum. Planta Med 1999; 65: 439–41.
107. Cancel LM, Tarbell JM. Rhamnan sulfate enhances the endothelial glycocalyx and decreases the LDL permeability of human coronary artery endothelial cells in vitro. Faseb J 2013; 27: 896.3.
108. Koch E, Malek FA. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders–preclinical and clinical studies. Planta Med 2011; 77: 1123–8.
109. Ebong EE, Lopez-Quintero SV, Rizzo V, Spray DC, Tarbell JM. Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. Integr Biol (Camb) 2014; 6: 338–47.
110. Peters W, Druppel V, Kusche-Vihrog K, Schubert C, Oberleithner H. Nanomechanics and sodium permeability of endothelial surface layer modulated by hawthorn extract WS 1442. PLoS One 2012; 7: e29972.
111. Giantsos-Adams K, Lopez-Quintero V, Kopeckova P, Kopecek J, Tarbell JM, Dull R. Study of the therapeutic benefit of cationic copolymer administration to vascular endothelium under mechanical stress. Biomaterials 2011; 32: 288–94.
112. Singha NC, Nekoroski T, Zhao C et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther 2015; 14: 523–32.
113. Jacobetz MA, Chan DS, Neesse A et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013; 62: 112–20.
114. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418–29.
115. Hingorani SR, Harris WP, Hendifar AE et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: interim results of a randomized phase II study. J Clin Oncol 2015; 33: 4006.
116. Nishida Y, Knudson W, Knudson CB, Ishiguro N. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 2005; 307: 194–203.
117. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849–57.
118. Twarock S, Freudenberger T, Poscher E et al. Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer 2011; 10: 30.
119. Hajime M, Shuichi Y, Makoto N et al. Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer 2007; 120: 2704–9.
120. Urakawa H, Nishida Y, Wasa J et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 2012; 130: 454–66.
121. Yoshihara S, Kon A, Kudo D et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 2005; 579: 2722–6.
122. Yates TJ, Lopez LE, Lokeshwar SD et al. Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst 2015; 107: djv085.
123. Potter DR, van Teeffelen JW, Vink H, van den Berg BM. Perturbed mechanotransduction by endothelial surface glycocalyx modification greatly impairs the arteriogenic process. Am J Physiol Heart Circ Physiol 2015; 107: H711-7: ajpheart 00257 2015.
124. Finlayson M. Modulation of CD44 Activity by A6-Peptide. Front Immunol 2015; 6: 135.
125. Weinstein T, Evron Z, Trebicz-Geffen M et al. beta-D-xylosides stimulate GAG synthesis in chondrocyte cultures due to elevation of the extracellular GAG domains, accompanied by the depletion of the intra-pericellular GAG pools, with alterations in the GAG profiles. Connect Tissue Res 2012; 53: 169–79.
126. van Wijk XM, Lawrence R, Thijssen VL et al. A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6F-GalNAc (Ac3). FASEB J 2015; 29: 2993–3002.
127. van Wijk XM, Thijssen VL, Lawrence R et al. Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis. ACS Chem Biol 2013; 8: 2331–8.
128. Barthel SR, Antonopoulos A, Cedeno-Laurent F et al. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem 2011; 286: 21717–31.
129. Ibrahim SA, Hassan H, Gotte M. MicroRNA regulation of proteoglycan function in cancer. FEBS J 2014; 281: 5009–22.
130. Agyare E, Kandimalla K. Delivery of Polymeric Nanoparticles to Target Vascular Diseases. J Biomol Res Ther 2014; 3: S1-001.
131. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 2014; 53: 12320–64.